|Systematic (IUPAC) name|
|Mol. mass||300.223 g/mol|
NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant, but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company. NS-2359 was also in clinical trials for the treatment of ADHD, phase II having been completed in 2007. A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.
Another scientific article on NS-2359 was recently (2011) published. As can be seen from reading the abstract to the citation, the compound failed to perform in clinical trials for the treatment of depression.
- "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression".
- Wilens, T. E.; Klint, T.; Adler, L.; West, S.; Wesnes, K.; Graff, O.; Mikkelsen, B. (2008). "A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD". Behavioral and Brain Functions 4: 24.
- Learned, S.; Graff, O.; Roychowdhury, S.; Moate, R.; Krishnan, K. R.; Archer, G.; Modell, J. G.; Alexander, R.; Zamuner, S.; Lavergne, A.; Evoniuk, G.; Ratti, E. (2011). "Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: Two randomized, placebo- and active-controlled clinical trials". Journal of Psychopharmacology 26 (5): 653–662.